RRID:SCR_023717 | Houston, TX 77030 | Pipeline Development, Plate Reader, Assay Development, Automated Liquid Handling, High Content Screening, High-throughput Screening, Biochemical Analysis, Image Aquisition, Image Processing And Analysis, Cell Culture, Cell Imaging, Inhibitor Screening, Irradiation, Computational - Bioinformatics, Computational - Biostatistics, Confocal Microscopy, Consultation, Live Cell Imaging, Data Analysis, Data Analysis And Interpretation, Data Processing, Small Molecule Compound Screening, Data Visualization | 06/23/2023 |
RRID:SCR_022214 | Houston, TX 77030 | Assay Development, Automated Liquid Handling, Biochemical Analysis, Cell Culture, Cell Imaging, Computational - Bioinformatics, Computational - Biostatistics, Computer-assisted Neuron Tracing And Analysis, Confocal Microscope With FCS/FLIM Capabilities , Confocal Microscopy, Consultation, Data Analysis, Data Analysis And Interpretation, Data Processing, Data Processin | 04/27/2022 |
RRID:SCR_022200 | Houston, TX 77030 | Protein Extraction/Purification, Cloning, Isothermal Titration Calorimetry (ITC), Isothermal Titration Calorimetry, Molecular Construct Services, Nucleic Acid Extraction, Protein Production, SDS-PAGE, Surface Plasmon Resonance (SPR), Surface Plasmon Resonance, Western Blot | 04/19/2022 |
RRID:SCR_021637 | bryan, TX 77807 | In-vivo Imaging, Cell Imaging, Confocal Microscopy, Data Processing And Interpretation, Data Analysis | 08/09/2021 |
Texas A&M Health Science Center
2121 W. Holcombe Blvd
Texas A&M Institute of Biosciences and Technology
Houston, TX 77030
United Stateshttps://vpr.tamu.edu/core_facility/high-throughput-research-and-screening-center/cite this facility
Clifford Stephan
Last Updated: 04/27/2022
The Combinatorial Drug Discovery Program (CDDP) resides in the Texas A&M Health Science Center’s Institute of Biosciences and Technology, Houston, TX. This core provides industry standard high throughput screening and automated microscopy capabilities to scientists performing drug discovery research. The core provides many benefits, such as access to an automated infrastructure that is capable of supporting both both phenotypic and biochemical targets. The CDDP provides ready access to collections of current FDA-approved drugs and clinical candidates exhibiting the ‘drug-like’ qualities of acceptable solubility, desirable ADME/toxicology properties and adequate bioavailability. These properties are important for rapid advancement of new agents into successful preclinical and clinical trials by discovering new therapeutic vulnerabilities alone or in combinations. The CDDP also has collections of mechanistically annotated informer sets that are pathway specific modulators for studying mechanism of action or target identification. The core also has collections of natural products and diverse sets of small molecules that can be interrogated for new target discovery. The greatest benefit of the core; however, is its fulltime professional staff. The screening team is composed of highly experienced biologists, biochemists, pharmacologists and data scientists with both pharmaceutical industry and academic experience. Each project is individually evaluated and a team of scientists from the CDDP is created to fit the specific needs of the project from assay design and development through primary, secondary and orthogonal screening. The team is committed to providing an integrated and highly collaborative program with every investigator.
Services are offerred outside of Texas A&M Health Science Center
Consulting is offerred outside of Texas A&M Health Science Center
